Targeting leptin signaling by using the peptide LDFI, or blocking JAK2/STAT3 signaling completely abrogated these effects, suggesting that the possibility that pharmacologically blocking leptin signaling might attenuate Notch activity in GBM. This evidence concerns the gene STAT3 and glioblastoma.